Company intelligence / Profile preview

Starling Locke Capital Funds

Vaduz, Liechtenstein

Ownership: Private
Development stage: Other

Overview

Starling Locke Capital Funds SICAV is an investment fund registered in Vaduz, Liechtenstein. Founded in 2020, it operates as an Aktiengesellschaft (public limited company) focusing on alternative investments. While it may invest in life science, biotech, pharma, or healthcare companies (e.g., X-Therma), it does not directly engage in research, development, or operation within these sectors, nor does it have a therapeutic pipeline or associated clinical programs.

Industry: Investors

Beyond the preview

Go deeper on Starling Locke Capital Funds.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Starling Locke Capital Funds.

Explore the full profile